跳至主要内容
临床试验/PACTR201705002266194
PACTR201705002266194Other未知

The pre-emptive use of pregabalin may reduce the incidence of postmasectomy pain syndrome following breast cancer surgery: a comparitive study

ational Cancer Institute0 个研究点目标入组 210 人开始时间: 2017年5月5日最近更新:
适应症

试验速览

阶段
未知
状态
Other
发起方
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Year(s) 至 60 Year(s)(—)
性别
Female

入选标准

  • Patients scheduled for elective breast surgery {either modified radical mastectomy(MRM) or conservative breast surgery (CBS)}combined with axillary dissection. ASA physical status I-II-III

排除标准

  • -History of pregabalin or gabapentin allergy.
  • -History of allergy to NSAIDs, morphine and paracetamol.
  • -Pregnancy and lactation.
  • -BMI > 40 kg/m^2.
  • -Patients with major liver, renal, cardiorespiratory,endocrinal or haematological disorder.
  • -Patients with preexisting pain which necessitates morphine at daily dose of 30 mg or more (or equivalent opioids).
  • History of pregabalin intake in the preceding 3 months.
  • -History of drug abuse.
  • -Expected another breast surgery in the subsequent period.
  • -Neuropsychiatric disorder.

研究者

发起方
ational Cancer Institute

相似试验

Postmastectomy Pai | 临床试验